[Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update].

[1]  A. Law,et al.  A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. , 2010, The Journal of antimicrobial chemotherapy.

[2]  H. Jafri,et al.  A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia , 2010, The Pediatric infectious disease journal.

[3]  E. Anaissie,et al.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Á. Soriano,et al.  Candida spp. bloodstream infection: influence of antifungal treatment on outcome. , 2010, The Journal of antimicrobial chemotherapy.

[5]  J. Perfect,et al.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  G. Klintmalm,et al.  Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Russell E. Lewis,et al.  Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001‐2007) , 2009, Cancer.

[8]  P. Mann,et al.  Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species , 2009, Antimicrobial Agents and Chemotherapy.

[9]  D. Kaufman,et al.  Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants , 2009, The Pediatric infectious disease journal.

[10]  D. Marriott,et al.  Determinants of mortality in non-neutropenic ICU patients with candidaemia , 2009, Critical care.

[11]  J. Rello,et al.  Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. , 2009, International journal of antimicrobial agents.

[12]  Nina Singh,et al.  Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Marriott,et al.  Not Just Little Adults: Candidemia Epidemiology, Molecular Characterization, and Antifungal Susceptibility in Neonatal and Pediatric Patients , 2009, Pediatrics.

[14]  P. Charles,et al.  Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study , 2009, Critical care medicine.

[15]  D. Kaufman,et al.  Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates , 2009, The Pediatric infectious disease journal.

[16]  François Gouin,et al.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) , 2009, Critical care medicine.

[17]  S. Jaffar,et al.  Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures , 2009, AIDS.

[18]  H. Jafri,et al.  A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients , 2009, Pediatrics.

[19]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Nolla,et al.  Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[21]  P. Martín-Dávila,et al.  Prophylaxis With Caspofungin for Invasive Fungal Infections in High-Risk Liver Transplant Recipients , 2009, Transplantation.

[22]  E. Lanino,et al.  Voriconazole for Cryptococcal Meningitis in Children with Leukemia or Receiving Allogeneic Hemopoietic Stem Cell Transplant , 2009, Journal of chemotherapy.

[23]  C. Junghanss,et al.  Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) , 2009, Annals of Hematology.

[24]  Mats O. Karlsson,et al.  Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.

[25]  S. Coffin,et al.  Pediatric Antifungal Utilization: New Drugs, New Trends , 2008, The Pediatric infectious disease journal.

[26]  T. Zaoutis,et al.  Caspofungin for the Treatment of Pediatric Fungal Infections , 2008, The Pediatric Infectious Disease Journal.

[27]  E. Bouza,et al.  Epidemiology of candidemia in intensive care units. , 2008, International journal of antimicrobial agents.

[28]  F. Meunier,et al.  The First European Conference on Infections in Leukaemia - ECIL1: a current perspective. , 2008, European journal of cancer.

[29]  D. Kaufman,et al.  Population Pharmacokinetics of Fluconazole in Young Infants , 2008, Antimicrobial Agents and Chemotherapy.

[30]  F. Queiroz-Telles,et al.  Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial , 2008, The Pediatric infectious disease journal.

[31]  F. Dromer,et al.  Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis , 2008, PloS one.

[32]  S. Jaffar,et al.  High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Hacımustafaoğlu,et al.  Nosocomial candidaemia in children: results of a 9‐year study , 2008, Mycoses.

[34]  P. Rohrlich,et al.  Adjuvant corticosteroid therapy for chronic disseminated candidiasis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  A. Pasqualotto,et al.  Voriconazole plasma monitoring , 2008, Archives of Disease in Childhood.

[36]  M. Wagener,et al.  Antifungal Management Practices in Liver Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  J. Heitman,et al.  Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against Cryptococcus neoformans Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with Cryptococcosis , 2007, Antimicrobial Agents and Chemotherapy.

[38]  K. Marr,et al.  Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients , 2007, British journal of haematology.

[39]  R. Betts,et al.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  N. Kartsonis,et al.  Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. , 2007, Journal of critical care.

[41]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[42]  A. Maloney,et al.  EFFICACY AND SAFETY OF CASPOFUNGIN FOR THE EMPIRIC MANAGEMENT OF FEVER IN NEUTROPENIC CHILDREN , 2007, The Pediatric infectious disease journal.

[43]  S. Fridkin,et al.  Impact of early central venous catheter removal on outcome in patients with candidaemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  R. Betts,et al.  Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.

[45]  S. Husain,et al.  Fungal infections in solid organ transplantation. , 2007, Medical mycology.

[46]  D. Pittet,et al.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.

[47]  C. Blyth,et al.  Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review , 2007, Pediatrics.

[48]  J. Heitman,et al.  Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. , 2007, The Journal of infectious diseases.

[49]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[50]  G. Kearns,et al.  The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants , 2006, The Pediatric infectious disease journal.

[51]  J. Yoder,et al.  EFFICACY AND SAFETY OF CASPOFUNGIN THERAPY IN CHILDREN WITH INVASIVE FUNGAL INFECTIONS , 2006, The Pediatric infectious disease journal.

[52]  K. Matsue,et al.  Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  D. Kaufman,et al.  Patterns of Fungal Colonization in Preterm Infants Weighing Less Than 1000 Grams at Birth , 2006, The Pediatric infectious disease journal.

[54]  B. Stoll,et al.  The Association of Third-Generation Cephalosporin Use and Invasive Candidiasis in Extremely Low Birth-Weight Infants , 2006, Pediatrics.

[55]  K. Garey,et al.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  J. Guarro,et al.  Efficacy of Voriconazole in a Guinea Pig Model of Invasive Trichosporonosis , 2006, Antimicrobial Agents and Chemotherapy.

[57]  D. Kaufman,et al.  Changing Incidence of Candida Bloodstream Infections Among NICU Patients in the United States: 1995–2004 , 2006, Pediatrics.

[58]  M. Falagas,et al.  Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials* , 2006, Critical care medicine.

[59]  A. Webster,et al.  Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. , 2006, The Journal of antimicrobial chemotherapy.

[60]  Benjamin J Park,et al.  Candidemia in Neonatal Intensive Care Units: Barcelona, Spain , 2006, The Pediatric infectious disease journal.

[61]  D. Benjamin,et al.  Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections , 2006, Antimicrobial Agents and Chemotherapy.

[62]  M. Choti,et al.  Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy , 2006, Journal of Clinical Microbiology.

[63]  J. Rabkin,et al.  Invasive Fungal Infections in Low‐Risk Liver Transplant Recipients: A Multi‐Center Prospective Observational Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[64]  F. Dromer,et al.  Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis , 2006, Antimicrobial Agents and Chemotherapy.

[65]  William Oh,et al.  Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2006, Pediatrics.

[66]  D. Benjamin,et al.  New antifungal agents under development in children and neonates , 2005, Current opinion in infectious diseases.

[67]  G. Hempel,et al.  Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates , 2005, Antimicrobial Agents and Chemotherapy.

[68]  J. Berlin,et al.  The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  G. Klintmalm,et al.  Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. , 2005, Transplantation.

[70]  J. Heitman,et al.  Antifungal Management Practices and Evolution of Infection in Organ Transplant Recipients with Cryptococcus Neoformans Infection , 2005, Transplantation.

[71]  C. Viscoli,et al.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial , 2005, The Lancet.

[72]  C. Mengoli,et al.  Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis , 2005, Intensive Care Medicine.

[73]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[74]  A. Shad,et al.  Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients , 2005, Antimicrobial Agents and Chemotherapy.

[75]  G. Klintmalm,et al.  An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  W. Steinbach.  Antifungal agents in children. , 2005, Pediatric clinics of North America.

[77]  E. Roilides,et al.  Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. , 2005, Journal of pediatric hematology/oncology.

[78]  J. Perfect,et al.  Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  S. Fridkin,et al.  Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 , 2005, Journal of Clinical Microbiology.

[80]  L. Pagano,et al.  Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature , 2005, Journal of Clinical Microbiology.

[81]  T. Walsh,et al.  Efficacy and Safety of Amphotericin B Lipid Complex in 548 Children and Adolescents With Invasive Fungal Infections , 2005, The Pediatric infectious disease journal.

[82]  T. Walsh,et al.  Caspofungin Therapy of Neonates With Invasive Candidiasis , 2004, The Pediatric infectious disease journal.

[83]  R. Piarroux,et al.  Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients(*) , 2004, Critical care medicine.

[84]  M. Pfaller,et al.  Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus , 2004, Journal of Clinical Microbiology.

[85]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[86]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[87]  N. White,et al.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial , 2004, The Lancet.

[88]  H. Danawi,et al.  Management of central venous catheters in patients with cancer and candidemia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  U. Intusoma,et al.  Mother-to-child transmission of cryptococcus neoformans. , 2004, The Pediatric infectious disease journal.

[90]  D. Pittet,et al.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. , 2003, The Lancet. Infectious diseases.

[91]  L. Sirota,et al.  Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. , 2003, Journal of Antimicrobial Chemotherapy.

[92]  E. Leibovitz,et al.  High-Dose Liposomal Amphotericin B in the Therapy of Systemic Candidiasis in Neonates , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[93]  J. Rex,et al.  Amphotericin B: time for a new "gold standard". , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  W. Shearer,et al.  Trichosporon pullulans infection in 2 patients with chronic granulomatous disease: an emerging pathogen and review of the literature. , 2003, The Journal of allergy and clinical immunology.

[95]  S. Senn,et al.  A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. , 2003, Clinical therapeutics.

[96]  J. L. López Sastre,et al.  Neonatal Invasive Candidiasis: A Prospective Multicenter Study of 118 Cases , 2003, American journal of perinatology.

[97]  R. Chapman.  Candida infections in the neonate , 2003, Current opinion in pediatrics.

[98]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[99]  R. Auckenthaler,et al.  Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination , 2002, Intensive Care Medicine.

[100]  W. Poole,et al.  Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. , 2002, Pediatrics.

[101]  Cheng-Hsien Lu,et al.  Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[102]  L. Saiman,et al.  Risk factors for Candida species colonization of neonatal intensive care unit patients. , 2001, The Pediatric infectious disease journal.

[103]  P. Lipsett,et al.  Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients , 2001, Annals of surgery.

[104]  M. Miyaji,et al.  Trichosporon species infection in bone marrow transplanted patients. , 2001, Diagnostic microbiology and infectious disease.

[105]  E. Buescher,et al.  Should Central Venous Catheters Be Removed as Soon as Candidemia Is Detected in Neonates? , 2000, Pediatrics.

[106]  R. Faix,et al.  Persistently positive cultures and outcome in invasive neonatal candidiasis , 2000, The Pediatric infectious disease journal.

[107]  D. Noyola,et al.  Candidal meningitis in neonates: a 10-year review. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[108]  A. Penk,et al.  Treatment of candidal infections with fluconazole in neonates and infants. , 2000, European journal of medical research.

[109]  L. Saiman,et al.  Risk factors for candidemia in Neonatal Intensive Care Unit patients , 2000, The Pediatric infectious disease journal.

[110]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[111]  Joseph Heitman,et al.  Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[112]  G. Noel,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. , 1999, The Journal of pediatrics.

[113]  S. Chanock,et al.  Amphotericin B lipid complex in pediatric patients with invasive fungal infections. , 1999, The Pediatric infectious disease journal.

[114]  P. Francioli,et al.  Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. , 1999, Critical care medicine.

[115]  J. Rowen,et al.  Management of Neonatal Candidiasis , 1998 .

[116]  A. Scarcella,et al.  Liposomal amphotericin B treatment for neonatal fungal infections. , 1998, The Pediatric infectious disease journal.

[117]  S. Chanock,et al.  Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis , 1997, Antimicrobial agents and chemotherapy.

[118]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[119]  R. Manfredi,et al.  Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. , 1997, International journal of STD & AIDS.

[120]  J. Singer,et al.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[121]  P. Cooper,et al.  Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. , 1996, The Pediatric infectious disease journal.

[122]  E. Anaissie,et al.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  T. Walsh,et al.  Cryptococcosis in human immunodeficiency virus-infected children. , 1996, The Pediatric infectious disease journal.

[124]  W. Jarvis.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[125]  A. Rowley,et al.  Candidemia in a pediatric population. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[126]  B. Bostrom,et al.  Pharmacokinetics of Fluconazole in Immune‐Compromised Children With Leukemia or Other Hematologic Disease , 1995, Pharmacotherapy.

[127]  A. Bava,et al.  Flucytosine+fluconazole association in the treatment of a murine experimental model of cryptococcosis. , 1994, Revista do Instituto de Medicina Tropical de Sao Paulo.

[128]  R. Auckenthaler,et al.  Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.

[129]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[130]  W. Graninger,et al.  Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[131]  Report of the Committee on Infectious Diseases , 1994 .

[132]  K. Hoppu,et al.  Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life , 1993, Clinical pharmacology and therapeutics.

[133]  T. Walsh,et al.  Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. , 1992, The Journal of pediatrics.

[134]  D. R. Weber,et al.  Hepatosplenic candidiasis: successful treatment with fluconazole. , 1991, The American journal of medicine.

[135]  E. Anaissie,et al.  Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. , 1991, The American journal of medicine.

[136]  R. Allendoerfer,et al.  Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis , 1991, Antimicrobial Agents and Chemotherapy.

[137]  I. Fong,et al.  Pharmacokinetics of Fluconazole in Serum and Cerebrospinal Fluid in a Patient with AIDS and Cryptococcal Meningitis , 1990, Pharmacotherapy.

[138]  R. Kliegman,et al.  Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. , 1990, The Journal of pediatrics.

[139]  K. Butler,et al.  Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates , 1990, The Pediatric infectious disease journal.

[140]  S. Kaplan,et al.  Pharmacokinetics of amphotericin B in infants and children. , 1987, The Journal of infectious diseases.

[141]  R. Jelliffe,et al.  Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  E. Bryce,et al.  Successful Treatment with Caspofungin of Hepatosplenic Candidiasis Resistant to Liposomal Amphotericin B , 2010 .

[143]  Aseem Kumar,et al.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) , 2010 .

[144]  Jay Steingrub,et al.  International study of the prevalence and outcomes of infection in intensive care units , 2009 .

[145]  N. Khardori.  Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? , 2009 .

[146]  S. Deresinski,et al.  Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[147]  C. Prober.  Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2007 .

[148]  P. Gokhale,et al.  Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report , 2005, Journal of Cancer Research and Clinical Oncology.

[149]  M. Saag,et al.  Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[150]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[151]  M. Saag,et al.  Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis , 2000 .

[152]  R. Finberg,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, The New England journal of medicine.

[153]  J. Rowen,et al.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group. , 1998, The Pediatric infectious disease journal.

[154]  A. Sitges-Serra,et al.  Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.

[155]  J. Rex,et al.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. , 1994, The New England journal of medicine.

[156]  W. Graninger,et al.  Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group. , 1994, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[157]  J. Hall,et al.  Amphotericin B dosage for disseminated candidiasis in premature infants. , 1987, Journal of perinatology : official journal of the California Perinatal Association.